skip to main content
Idioma:
Resultados 1 2 3 4 next page
Mostrar Somente
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study

González-Martín, Antonio ; Chung, Hyun Cheol ; Saada-Bouzid, Esma ; Yanez, Eduardo ; Senellart, Helene ; Cassier, Philippe A. ; Basu, Bristi ; Corr, Bradley R. ; Girda, Eugenia ; Dutcus, Corina ; Okpara, Chinyere E. ; Ghori, Razi ; Jin, Fan ; Groisberg, Roman ; Lwin, Zarnie

Gynecologic oncology, 2024-07, Vol.186, p.182-190 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
2
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study

Chung, Hyun Cheol ; Saada‐Bouzid, Esma ; Longo, Federico ; Yanez, Eduardo ; Im, Seock‐Ah ; Castanon, Eduardo ; Desautels, Danielle N. ; Graham, Donna M. ; Garcia‐Corbacho, Javier ; Lopez, Juanita ; Dutcus, Corina ; Okpara, Chinyere E. ; Ghori, Razi ; Jin, Fan ; Groisberg, Roman ; Korakis, Iphigenie

Cancer, 2024-06 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
3
Abstract CT283: Phase 3 MK-2870-007 study: MK-2870 (SKB264) plus pembrolizumab vs pembrolizumab alone as first-line treatment for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50
Abstract CT283: Phase 3 MK-2870-007 study: MK-2870 (SKB264) plus pembrolizumab vs pembrolizumab alone as first-line treatment for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract CT283: Phase 3 MK-2870-007 study: MK-2870 (SKB264) plus pembrolizumab vs pembrolizumab alone as first-line treatment for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50

Frost, Nikolaj ; Ghori, Razi ; Roy, Ananya ; Nunes, Ana Tablante ; Yang, James Chih-Hsin

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.CT283-CT283 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
4
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma

Woyach, Jennifer A ; Stephens, Deborah M ; Flinn, Ian W ; Bhat, Seema A ; Savage, Ronald E ; Chai, Feng ; Eathiraj, Sudharshan ; Reiff, Sean D ; Muhowski, Elizabeth M ; Granlund, Lindsey ; Szuszkiewicz, Lyndsey ; Wang, Wayne ; Schwartz, Brian ; Ghori, Razi ; Farooqui, Mohammed Z H ; Byrd, John C

Cancer discovery, 2024-01, Vol.14 (1), p.66-75

United States

Texto completo disponível

Citações Citado por
5
P628: UPDATED ANALYSIS OF BELLWAVE‐001: A PHASE 1/2 OPEN‐LABEL DOSE‐EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B‐CELL MALIGNANCIES
P628: UPDATED ANALYSIS OF BELLWAVE‐001: A PHASE 1/2 OPEN‐LABEL DOSE‐EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B‐CELL MALIGNANCIES
Material Type:
Artigo 		Adicionar ao Meu Espaço

P628: UPDATED ANALYSIS OF BELLWAVE‐001: A PHASE 1/2 OPEN‐LABEL DOSE‐EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B‐CELL MALIGNANCIES

Woyach, Jennifer ; Flinn, Ian W. ; Awan, Farrukh ; Eradat, Herbert ; Brander, Danielle M. ; Tees, Michael ; Parikh, Sameer ; Phillips, Tycel ; Ghori, Razi ; Paydar, Ima ; Farooqui, Mohammed Z. H. ; Byrd, John C. ; Stephens, Deborah

HemaSphere, 2023-08, Vol.7 (S3), p.e7809236-n/a [Periódico revisado por pares]

Philadelphia, PA: Lippincott Williams & Wilkins

Texto completo disponível

Citações Citado por
6
Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study
Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

Woyach, Jennifer A. ; Flinn, Ian W. ; Awan, Farrukh T. ; Eradat, Herbert ; Brander, Danielle ; Tees, Michael ; Parikh, Sameer A. ; Phillips, Tycel J. ; Ghori, Razi ; Reddy, Nishitha M. ; Farooqui, Mohammed Z.H. ; Byrd, John C. ; Stephens, Deborah M.

Blood, 2022-11, Vol.140 (Supplement 1), p.7004-7006 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
7
Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAF V600E/K -mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3
Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAF V600E/K -mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAF V600E/K -mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3

Ribas, Antoni ; Ferrucci, Pier Francesco ; Atkinson, Victoria ; Stephens, Rosalie ; Long, Georgina V. ; Lawrence, Donald P. ; Del Vecchio, Michele ; Hamid, Omid ; Schmidt, Henrik ; Schachter, Jacob ; Queirolo, Paola ; Miller, Wilson H. ; Carlino, Matteo S. ; Di Giacomo, Anna Maria ; Svane, Inge Marie ; Ghori, Razi ; Singh, Rohini ; Diede, Scott J. ; Ascierto, Paolo Antonio

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9516-9516 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
8
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
Material Type:
Artigo 		Adicionar ao Meu Espaço

KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation

Maio, Michele ; Carlino, Matteo S. ; Joshua, Anthony M. ; McWhirter, Elaine ; Ribas, Antoni ; Ascierto, Paolo A. ; Miller, Wilson H. ; Butler, Marcus O. ; Ferrucci, Pier Francesco ; Zielinski, Robert R. ; Del Vecchio, Michele ; Gasal, Eduard ; Ghori, Razi ; Diede, Scott J. ; Croydon, Elizabeth ; Hamid, Omid

European journal of cancer (1990), 2022-01, Vol.160, p.1-11 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
9
Pembrolizumab combined with carfilzomib and low‐dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE‐023 study
Pembrolizumab combined with carfilzomib and low‐dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE‐023 study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pembrolizumab combined with carfilzomib and low‐dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE‐023 study

Moreau, Philippe ; Ghori, Razi ; Farooqui, Mohammed ; Marinello, Patricia ; San Miguel, Jesus

British journal of haematology, 2021-07, Vol.194 (1), p.e48-e51 [Periódico revisado por pares]

England: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
10
LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort
LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort
Material Type:
Artigo 		Adicionar ao Meu Espaço

LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort

Gomez-Roca, Carlos A. ; Yanez, Eduardo ; Im, Seock-Ah ; Castanon Alvarez, Eduardo ; Senellart, Hélène ; Doherty, Mark ; Garcia-Corbacho, Javier ; Lopez, Juanita Suzanne ; Basu, Bristi ; Maurice-Dror, Corinne ; Gill, Sanjeev Singh ; Ghori, Razi ; Kubiak, Peter ; Jin, Fan ; Norwood, Kevin Glen ; Chung, Hyun Cheol Cheol

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3564-3564 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (30)
  2. Revistas revisadas por pares (29)

Data de Publicação 

De até
Refinar
  1. Antes de2017  (2)
  2. 2017Até2018  (2)
  3. 2019Até2020  (13)
  4. 2021Até2023  (12)
  5. Após 2023  (4)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.